Demographic data from the post-market IN.PACT AV Access Study suggests that the patient cohort had more complex lesions, allowing greater identification for subsets of groups that may need to be investigated.

Dr Sanjay Misra (Mayo Clinic, Rochester, US) joins us to discuss the demographic data from the post-market IN.PACT AV Access approval study (NCT03041467; Medtronic Endovascular), investigating the safety and efficacy of the IN.PACT AV DCB with paclitaxel treatment for dysfunctional arteriovenous fistulas and arteriovenous grafts using real-world evidence from 17 US clinical sites. The study included a primary and an extended cohort, and the primary safety endpoints in both cohorts were infection, infestation and serious adverse events through 12 months.

Interview Questions:
1. What is the background behind the IN.PACT AV Access demographic study?
2. Could you tell us about the unique features of the IN.PACT AV DCB?
3. What was the study design and patient population?
4. What were the key demographic findings from this postaproval study?

Recorded remotely from Rochester, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Vascular.